Overall, Eisai generated 601.2 billion yen (nearly $4 billion) over the last nine months of 2024, signaling 9% growth year-on-year. For the entire 12-month stretch ending March 31, the company ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...

Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...

Eisai reported strong Q3 2024 performance driven by its leading products, particularly LEQEMBI, which saw robust sales growth across key regions. Management expressed confidence in achieving its ...

Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), opens new tab Alzheimer's ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug Administration (FDA) for monthly maintenance dosing. The anti-amyloid drug was ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Visakhapatnam: People swarmed Visakhapatnam Fishing Harbour, one of the largest in the country, on Sunday morning. They purchased 150 tonnes of various varieties of fish. Fishermen have been ...

A partnership between Eisai and Lifenet that aims to improve insurance cover for people with early dementia has generated its first policy, part of an effort by the pharma group to develop an ...

A halt is being provided to the Maha Kumbh Mela specials, being operated from Visakhapatnam, at Kottavalasa, for the convenience of pilgrims and devotees from North Andhra region going to the ...

(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's Alzheimer's drug Leqembi, the companies said on Monday. The drug ...